Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world effects of novel androgen receptor axis-targeted agents on oncological outcomes in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study.
Fujita N, Hatakeyama S, Tabata R, Okita K, Kido K, Hamano I, Tanaka T, Noro D, Tokui N, Suzuki Y, Yoneyama T, Hashimoto Y, Sato S, Ohyama C. Fujita N, et al. Among authors: tabata r. Prostate Int. 2024 Mar;12(1):46-51. doi: 10.1016/j.prnil.2023.12.002. Epub 2023 Dec 19. Prostate Int. 2024. PMID: 38523900 Free PMC article.
Effects of apalutamide dose reduction on skin-related adverse events in patients with advanced prostate cancer: A multicenter retrospective study.
Oishi T, Hatakeyama S, Tabata R, Fujimori D, Kawashima Y, Tanaka R, Ishii N, Miura H, Tanaka T, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Sato S, Ohyama C. Oishi T, et al. Among authors: tabata r. Prostate. 2023 Feb;83(2):198-203. doi: 10.1002/pros.24453. Epub 2022 Oct 31. Prostate. 2023. PMID: 36314250
Comparison of neoadjuvant chemohormonal therapy vs. extended pelvic lymph-node dissection in high-risk prostate cancer treated with robot-assisted radical prostatectomy.
Oishi T, Hatakeyama S, Tabata R, Fujimori D, Fukuda M, Shinozaki T, Ishii N, Iwamura H, Okamoto T, Yamamoto H, Yoneyama T, Hashimoto Y, Sato S, Ohyama C. Oishi T, et al. Among authors: tabata r. Sci Rep. 2023 Mar 1;13(1):3436. doi: 10.1038/s41598-023-30627-7. Sci Rep. 2023. PMID: 36859718 Free PMC article.
Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma.
Numakura K, Sekine Y, Hatakeyama S, Muto Y, Sobu R, Kobayashi M, Sasagawa H, Kashima S, Yamamto R, Nara T, Akashi H, Tabata R, Sato S, Saito M, Narita S, Ohyama C, Habuchi T. Numakura K, et al. Among authors: tabata r. Cancer Med. 2023 Aug;12(16):16837-16845. doi: 10.1002/cam4.6306. Epub 2023 Jul 5. Cancer Med. 2023. PMID: 37403728 Free PMC article.
235 results